Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
By
Victoria Song
Summary
This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (people taking medications like Ozempic, Wegovy, Mounjaro for weight loss or diabetes). The author attends a launch event for the Withings Body Smart scale, which features a 'GLP-1 program' that tracks muscle mass, fat mass, and other metrics relevant to those on these medications. The piece critically analyzes the trend of 'built for GLP-1' marketing, exploring whether these features genuinely address user needs or are simply opportunistic branding. It discusses the broader implications of GLP-1 drugs on the health and fitness industry, including how companies are pivoting their products and messaging to capture this growing market, while questioning the actual utility and evidence behind these specialized features.
Source
bskyHealth tech companies rush to market 'GLP-1 ready' products as weight loss drug trend growstheverge.comKey quotes
· 4 pulled'What does it mean to be built for GLP-1 users?' asks the author, questioning the marketing hype behind the trend.
'It's not that these features aren't useful — it's that they're being marketed as revolutionary when they're often just repackaged existing technology.'
'The GLP-1 boom is reshaping the health and fitness industry, and companies are scrambling to figure out how to position themselves.'
'There's a real risk that people will buy these products expecting them to solve problems that they simply can't address.'
You might also wanna read
Experts warn easy access to GLP-1 drugs may increase eating disorder risks
Experts are raising concerns that the widespread availability of GLP-1 drugs (like Ozempic and Wegovy) through telemedicine and oral formula
mdsc.pe·1d ago
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·5mo ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·2d ago
Impact of GLP-1s on Life Insurance and Insights from a Health Tech Event
The article discusses the impact of GLP-1s on life insurance and shares insights from a health tech event in Amsterdam. It also highlights t
glp1digest.com·11mo ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development
The article reveals previously untold history about early GLP-1 drug development in the late 1980s and early 1990s. The author was part of w
statnews.com·5mo ago